Topic Hub
25 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 25 of 25 clinical reviews.
A physician-reviewed, evidence-based guide to using romosozumab (Evenity) in patients with severe osteoporosis after bariatric surgery, covering pharmacokinetics, dosing, calcium repletion, and transition strategies.
Read clinical reviewA clinical review of whether romosozumab (Evenity) causes appetite or cravings changes, what the trial data show, and how to counsel patients starting this osteoporosis therapy.
Read clinical reviewA clinical review of romosozumab use in patients with autoimmune conditions, covering immunogenicity, drug interactions, cardiovascular signals, and dosing guidance for rheumatologists and endocrinologists.
Read clinical reviewA physician-level review of romosozumab's mechanism, BMD gains, fracture-reduction data from ARCH and FRAME, cardiovascular risk, and clinical sequencing strategy for severe osteoporosis.
Read clinical reviewA MD/PharmD-level review of the cancer risk signal associated with romosozumab (Evenity), including ARCH trial data, FDA label language, post-marketing surveillance findings, and clinical decision frameworks for prescribers.
Read clinical reviewA detailed clinical review of romosozumab (Evenity) cardiovascular risk, including ARCH trial data, FDA black box warning, post-marketing evidence, and patient selection guidance for severe osteoporosis treatment.
Read clinical reviewA physician-reviewed, primary-literature analysis of whether romosozumab (Evenity) affects cognitive function, including sclerostin biology, available trial data, and what patients with osteoporosis should know before starting therapy.
Read clinical reviewA physician-reviewed comparison of branded Evenity (romosozumab) and compounded romosozumab, covering clinical trial data, regulatory status, safety, dosing, and who qualifies for each option.
Read clinical reviewA GRADE-level review of romosozumab (Evenity) clinical trials, fracture-reduction data, cardiovascular safety, and guideline recommendations for severe osteoporosis management.
Read clinical reviewA clinical deep-dive into romosozumab (Evenity) hair loss and skin changes, covering trial data, proposed mechanisms, management strategies, and FDA labeling.
Read clinical reviewA clinical deep-dive into romosozumab's effect on liver function tests, hepatotoxicity risk, ALT/AST monitoring, and how ARCH trial data and FDA labeling inform prescribing decisions.
Read clinical reviewA clinical deep-dive into whether romosozumab (Evenity) affects mood, depression, anxiety, or cognition, with primary-literature citations, FDA safety data, and a practical prescribing framework.
Read clinical reviewA clinical deep-dive into how romosozumab (Evenity) affects bone metabolism, energy expenditure, and systemic physiology, with primary-literature citations and dosing guidance.
Read clinical reviewA clinician-level review of romosozumab (Evenity) standard dosing, the complete absence of validated microdosing protocols, fracture-risk evidence from ARCH and FRAME, and what physicians should know before considering any off-label dose modification.
Read clinical reviewA clinical deep-dive into how romosozumab (Evenity) affects skeletal muscle, which muscle-preservation strategies pair best with its 12-month anabolic window, and what the evidence says about concurrent resistance training, protein intake, and adjunct therapies.
Read clinical reviewA clinician-level guide to diagnosing and managing romosozumab plateau and non-response in severe osteoporosis, with primary-literature citations, dosing protocols, and sequential therapy strategies.
Read clinical reviewA physician-level guide to the romosozumab pre-surgery hold window, covering ARCH trial data, cardiovascular risk, timing protocols, and return-to-therapy decisions after orthopedic or elective surgery.
Read clinical reviewWhat happens to bone density and fracture risk when romosozumab (Evenity) is stopped? A clinical deep-dive covering the anabolic window, rebound bone loss, and the mandatory antiresorptive follow-on therapy backed by ARCH and FRAME trial data.
Read clinical reviewDoes romosozumab (Evenity) protect the kidneys or put them at risk? A physician-reviewed deep dive into ARCH trial data, sclerostin biology, phosphate handling, and dosing guidance for patients with CKD.
Read clinical reviewA clinical deep-dive into how season, temperature, sun exposure, vitamin D status, and patient scheduling affect romosozumab (Evenity) therapy for severe osteoporosis. Written for prescribers and informed patients.
Read clinical reviewA clinician-reviewed deep dive into whether romosozumab (Evenity) affects sexual function, libido, and hormone levels, with primary-literature citations and a practical prescribing framework.
Read clinical reviewA physician-reviewed deep dive into how romosozumab (Evenity) may affect sleep architecture, with primary-literature citations, dose details, and clinical guidance for prescribers and patients.
Read clinical reviewA clinician-level guide to managing romosozumab (Evenity) injections around travel, timezone changes, and missed-dose windows, with primary-literature citations and practical scheduling frameworks.
Read clinical reviewA physician-reviewed, week-by-week guide to romosozumab (Evenity) during your first month of treatment: injection procedure, early bone-turnover shifts, side effects, and what your prescriber monitors.
Read clinical reviewBoard-reviewed guidance on when and how to restart romosozumab (Evenity) after an acute illness interrupts therapy, with primary-literature citations, dosing timelines, and cardiovascular risk reassessment.
Read clinical review